《阿斯利康AstraZeneca（AZN）2025年第一季度业绩报告「LSE」（英文版）（36页）.pdf》由会员分享，可在线阅读，更多相关《阿斯利康AstraZeneca（AZN）2025年第一季度业绩报告「LSE」（英文版）（36页）.pdf（36页珍藏版）》请在三个皮匠报告上搜索。

1、Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 1 29 April 2025 AstraZeneca results:Q1 2025 Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambitionRevenue and EPS summary Q1 2025%Change$m Actual CER1 -

2、Product Sales 12,875 6 9 -Alliance Revenue 639 40 42 Product Revenue2 13,514 7 10 Collaboration Revenue 74 64 64 Total Revenue 13,588 7 10 Reported EPS($)1.88 34 32 Core3 EPS($)2.49 21 21 Key performance elements for Q1 2025(Growth numbers at constant exchange rates)Total Revenue up 10%to$13,588m,dr

3、iven by double-digitgrowth in Oncology and BioPharmaceuticals Growth in Total Revenue across all major geographic regions Core Operating profit increased 12%Core Tax rate of 16%in the quarter due to timing ofsettlements.Expectations for the full year Core tax rate are unchanged at 18-22%Core EPS inc

4、reased 21%to$2.49 Five positive Phase III readouts and 13 approvals in majorregions since the prior resultsPascal Soriot,Chief Executive Officer,AstraZeneca,said:Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.Already t

5、his year we have announced five positive Phase III study readouts,including most recently the highly anticipated DESTINY-Breast09 for Enhertu,as well as SERENA-6 for camizestrant and MATTERHORN for Imfinzi;the latter two of these will feature in the ASCO 2025 plenary sessions,reflecting the signific

6、ance of these data to the oncology community.Our company is firmly committed to investing and growing in the US and we continue to benefit from our broad-based source of revenue and global manufacturing footprint,including eleven production sites in the US covering small molecules,biologics as well